Navigation Links
Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America
Date:10/16/2008

SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will receive a Corporate Achievement Award from the Huntington's Disease Society of America (HDSA), which honors those companies that exemplify leadership in the fight against Huntington's disease and other neurodegenerative diseases. David Hung, M.D., president and chief executive officer of Medivation, will accept the award during the 12th Annual Guthrie Awards Dinner on Thursday, October 16, at the Waldorf Astoria in New York.

"We are honored to be recognized by the HDSA for our efforts to develop a treatment for Huntington's disease. We are committed to bringing Dimebon to market so patients can gain access to a drug that could truly improve how they, and their families, live with this terrible debilitating disease," said Dr. Hung. "We are encouraged by our Phase 2 trial findings, which, we believe, showed Dimebon to be the first investigational drug to demonstrate a significant benefit in any measure of cognitive function in patients with mild-to-moderate Huntington's disease in a well-controlled study."

Medivation is developing Dimebon, an orally available small molecule, to treat patients with mild-to-moderate Huntington's disease. The Company recently announced that it plans to continue further development of the drug with its new development partner Pfizer based on positive results seen in a Phase 2 trial. In addition, Medivation is evaluating Dimebon in a pivotal and confirmatory Phase 3 trial in patients with Alzheimer's disease.

About Huntington's Disease

Huntington's disease is a progressive, neurodegenerative disease that affects 30,000 patients in the U.S., with another 150,000 at risk. It is
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
2. Medivation Announces Participation in Upcoming Conferences
3. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
5. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
7. Medivation Announces Senior Management Promotions
8. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
9. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...bleEnergyCorp.announcedtodaythatthecompanyandtheOd...arded$2millionbyWashingtonState,sCommunityEconomic...hiptoconstructthestate,sfirstspecialtybiochemicalb...twillsignificantlyspeedthedevelopmentofourbiorefin...eMarbleEnergyCEOKellyOgilvie."WearegratefultotheGo...
(Date:11/24/2009)...all/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobals...atithassubmittedaMAAtotheEuropeanMedicinesAgencyfo...herapyindevelopment,forthetreatmentofType1Gaucherd...lucerasealfathathasbeensubmitted,withprevious,subm...globalsupplyshortageofthecurrentlyapprovedandmarke...
(Date:11/24/2009)...Customers with Partners Validated to Process and A... , Ottawa, ON (PRWEB) Nov...r of products for biological sample collection, st...ew global partner program. The program offers sign...munity and is designed to help partners scale and ...
(Date:11/23/2009)...rigami very high-tech origami. , Researchers at ...que for fabricating three-dimensional, single-crys...ling photolithography and a self-folding process d...y a few microns thick, offer mechanical bendabilit...same material. , "This is a completely different ...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
... /PRNewswire-FirstCall/ - Angiotech Pharmaceutical...d that its corporate partner, Boston Scientific Co...comes from a substudy of patients with left main c... Express(2)(R) Paclitaxel-Eluting Coronary Stent S...k SYNTAX trial, the first randomized, controlled c...
...ay 19 In an eleventh-hour attempt to smear Ted K...has issued a press release claiming that there was...ichard Rosenbloom, a key staff member of a subsidi...oup of dissident shareholders who have offered the...lection at the annual meeting scheduled for Wednes...
...w Projects Approved in Atlanta , , ATLANTA, May ...biotechnology convention, the Kansas Bioscience Au...investments as part of a $581 million initiative t...ate. , , The funding decisions made at the Bio In...ers of innovation in biomaterials and plant biolog...
Other Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 4
(Date:11/23/2009)...HAM, Ala. A new study by University of Alabama at... index (BMI) and co-existing medical conditions (c... observed among African-Americans compared to Cauc...blished online Nov. 23 in Cancer , a journal of t...tes that although BMI and co-morbidity are indepen...
(Date:11/23/2009)...like frogs and toads have existed for 360 million ...a new aquatic fungus is threatening to make many o...ember issue of Microbiology Today . , The fung...nd to be associated with waves of amphibian extinc...ia in the 1990,s. Bd infects over 350 amphibian sp...
(Date:11/23/2009)...ts have revealed how environmental irritants such ...to cough, in research published today in the Amer...cine . The authors of the study, from Imperial Col...ified the reaction inside the lungs that can trigg... irritants in the air. They suggest that their fin...
Breaking Biology News(10 mins):Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Research reveals exactly how coughing is triggered by environmental irritants 2Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 1Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 2Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 3Osseon Signs International Distribution Agreement With MBA Incorporado 57980 1Osseon Signs International Distribution Agreement With MBA Incorporado 57980 2Osseon Signs International Distribution Agreement With MBA Incorporado 57980 3GHX Joins the Oracle PartnerNetwork 57978 1GHX Joins the Oracle PartnerNetwork 57978 2GHX Joins the Oracle PartnerNetwork 57978 3
... of the biggest questions in modern oceanography i...arine biologists at the Monterey Bay Aquarium Rese...that helps answer this question, at least for anim...f Central California. After analyzing hundreds of ...leagues found that "sinkers"-the cast-off mucus ne...
...mas C. Quinn, M.D., a Johns Hopkins physician and ... 25 years leading major efforts to combat HIV and ...trategies and resources to confront the rapid "fem...sor of infectious diseases at Hopkins and a senior... and Infectious Disease, reports that women have i...
... of minuscule devices to spot cancer markers could... University researchers have found that molecular ...ody are readily detected in blood scanned by speci...cancer markers constitute only one hundred-billion...ddition to this exceptional accuracy and sensitivi...
Other Biology News:'Sinkers' provide missing piece in deep-sea puzzle 2'Sinkers' provide missing piece in deep-sea puzzle 3'Sinkers' provide missing piece in deep-sea puzzle 4AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Nanowires can detect molecular signs of cancer, scientists find 2Nanowires can detect molecular signs of cancer, scientists find 3
Custom siRNA, standard purity, annealed from Ambion
...es the premium quality siRNAs you need for your ge...y ordered online by providing either the 19-21 bas...ntisense siRNA sequences. (Also check out Ambion&#...ned siRNAs, which are already designed for you.) F...
Sheep Prolactin from Cell Sciences
Goat Anti-Human SCP3 / SYCP3 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Biology Products: